Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : momo-T/FIF -- Ignore unavailable to you. Want to Upgrade?

To: IRWIN JAMES FRANKEL who wrote (3344)	10/22/2005 3:31:17 PM
From: scaram(o)uche	Read Replies (1) \| Respond to of 12215

I.J.: Ouch, but good about the "fold" part. >> will keep a lot of attorneys off the dole << hurricanes, tsunamis, earthquakes, and now this. what a year. (thanks for the perspectives on debt, always upfront when thinking about an edge.) >> What are the chances of H5N1 reassociating into an easily transmissible human-to-human virus? How long will it take? Will FluMist confer any immunity however small? << 1. 99% plus. The number of humans on Earth is increasing, as is the demand for reproducible sources of tasty protein. 2. Haven't a clue. 3. Great question! They (MEDI) had that tiny bit of cross-reactivity data, and who is to say that a little T cell priming doesn't sneak in at some cross-reactive level that's not reflected in serology (B cell response)? Don't know, but it's a great question and one would hope that MEDI would follow up. Guess J.D. decided that folk in Belgium were sane and decided to stay. :-) Rick